Vazirani Asset Management LLC Has $1.06 Million Stake in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Vazirani Asset Management LLC increased its stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 250.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 350,000 shares of the biopharmaceutical company’s stock after acquiring an additional 250,000 shares during the quarter. Revance Therapeutics comprises about 3.3% of Vazirani Asset Management LLC’s portfolio, making the stock its 7th largest holding. Vazirani Asset Management LLC’s holdings in Revance Therapeutics were worth $1,064,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Natixis bought a new position in shares of Revance Therapeutics during the fourth quarter worth $31,000. Two Sigma Securities LLC bought a new position in shares of Revance Therapeutics during the fourth quarter worth $35,000. Alpine Global Management LLC bought a new position in shares of Revance Therapeutics during the fourth quarter worth $37,000. RPO LLC bought a new position in shares of Revance Therapeutics during the fourth quarter worth $55,000. Finally, Virtu Financial LLC bought a new position in shares of Revance Therapeutics during the third quarter worth $120,000. Institutional investors own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

RVNC has been the subject of several research reports. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. StockNews.com initiated coverage on shares of Revance Therapeutics in a research report on Sunday. They set a “hold” rating for the company. Nine equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $8.39.

Revance Therapeutics Stock Performance

Revance Therapeutics stock opened at $3.65 on Monday. The firm has a 50-day moving average price of $3.65 and a 200-day moving average price of $3.84. The firm has a market capitalization of $381.02 million, a PE ratio of -1.89 and a beta of 0.90. Revance Therapeutics, Inc. has a 12-month low of $2.30 and a 12-month high of $6.65.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.